PTCT insider uses 10b5-1 plan to exercise and sell 24,921 shares

Rhea-AI Filing Summary

PTC Therapeutics insider transactions: an executive exercised stock options and sold an equal number of shares under a pre-existing trading plan. On 10/03/2025 and 10/06/2025, the reporting person exercised stock options with an exercise price of $39.42 and acquired 24,921 shares in aggregate. The filing shows sales of 24,921 shares executed at weighted average prices ranging roughly from $64.00 to $67.29, producing reported sale prices such as $64.43, $65.47, and $66.44. Following these transactions the reporting person beneficially owns 103,901 shares.

The filing notes the trades were effected pursuant to a written Rule 10b5-1 plan adopted on 12/05/2024, and that the underlying options were originally granted on 01/05/2023 with a vesting schedule that began on 01/05/2024. The pattern—exercise at $39.42 and near-immediate sales at ~$64–$67—is consistent with option exercises followed by planned sales, leaving the reporting person with 103,901 shares after the reported activity.

Positive

• Trades executed under a documented Rule 10b5-1 plan adopted on 12/05/2024
• Options exercised at a $39.42 strike, demonstrating liquidity conversion of vested compensation
• Final beneficial ownership disclosed as 103,901 shares, maintaining transparent post-trade holdings

Negative

• Aggregate sales of 24,921 shares reduced the reporting person's holdings
• Immediate sales after exercise realize gains but decrease insider equity exposure

Insights

Corporate Governance Analyst

Options exercised and sales executed under a 10b5-1 plan, maintaining disclosure compliance.

The reporting person exercised multiple stock options with a $39.42 strike and acquired 24,921 shares across 10/03/2025–10/06/2025. The filer checked the box indicating these trades were made pursuant to a Rule 10b5-1 plan adopted on 12/05/2024, which provides an affirmative defense for pre-arranged trading.

This structure reduces insider timing concerns by documenting pre-authorization, but investors should note the overall beneficial holding fell to 103,901 shares immediately after the activity; watch for future Form 4s or plan termination notices for changes.

Equity Trading Analyst

Equal shares acquired and sold: 24,921 shares exercised then sold at weighted averages near $64–$67.

The filings list sales totaling 24,921 shares executed at reported weighted-average sale prices with ranges disclosed between $64.00 and $67.29. The option exercise price was $39.42, creating a per-share spread realized by the sales.

This indicates a sell-to-cover or monetization of vested options on 10/03/2025–10/06/2025. Market impact is likely limited given the modest share counts relative to typical public float, but monitor volume and any additional planned sales within the 10b5-1 schedule over the next quarter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boulding Mark Elliott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. VP AND CLO

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		M(1)		18,124	A	$39.42	122,025	D
Common Stock	10/03/2025		S(1)		3,100	D	$64.43(2)	118,925	D
Common Stock	10/03/2025		S(1)		6,124	D	$65.47(3)	112,801	D
Common Stock	10/03/2025		S(1)		7,400	D	$66.44(4)	105,401	D
Common Stock	10/03/2025		S(1)		1,500	D	$67.15(5)	103,901	D
Common Stock	10/03/2025		M(1)		2,266	A	$39.42	106,167	D
Common Stock	10/03/2025		S(1)		536	D	$64.43(6)	105,631	D
Common Stock	10/03/2025		S(1)		824	D	$65.73(7)	104,807	D
Common Stock	10/03/2025		S(1)		906	D	$66.63(8)	103,901	D
Common Stock	10/03/2025		M(1)		2,265	A	$39.42	106,166	D
Common Stock	10/03/2025		S(1)		550	D	$64.44(9)	105,616	D
Common Stock	10/03/2025		S(1)		838	D	$65.72(10)	104,778	D
Common Stock	10/03/2025		S(1)		877	D	$66.67(11)	103,901	D
Common Stock	10/06/2025		M(1)		2,266	A	$39.42	106,167	D
Common Stock	10/06/2025		S(1)		2,266	D	$65.07(12)	103,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$39.42	10/03/2025		M(1)			18,124	(13)	01/04/2033	Common Stock	18,124	$0	18,126	D
Stock Option (Right to Buy)	$39.42	10/03/2025		M(1)			2,266	(13)	01/04/2033	Common Stock	2,266	$0	15,860	D
Stock Option (Right to Buy)	$39.42	10/03/2025		M(1)			2,265	(13)	01/04/2033	Common Stock	2,265	$0	13,595	D
Stock Option (Right to Buy)	$39.42	10/06/2025		M(1)			2,266	(13)	01/04/2033	Common Stock	2,266	$0	11,329	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

8. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

9. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

10. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

11. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

12. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.72 to $65.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

13. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the PTC Therapeutics (PTCT) insider do on 10/03/2025–10/06/2025?

The reporting person exercised stock options at an exercise price of $39.42 and acquired 24,921 shares, then sold 24,921 shares at weighted-average prices roughly between $64.00 and $67.29.

Were the PTCT trades part of a pre-arranged plan?

Yes. The filer indicated the transactions were effected pursuant to a written Rule 10b5-1 plan adopted on 12/05/2024.

How many PTCT shares does the reporting person own after these transactions?

Following the reported transactions the reporting person beneficially owns 103,901 shares.

What was the option grant and vesting schedule noted in the filing?

The option was granted on 01/05/2023 and vests over four years with 25% vesting on 01/05/2024 and additional 6.25% of the original grant vesting each successive three-month period thereafter beginning 04/05/2024.

What prices were reported for the sales in the Form 4 for PTCT?

The filing reports weighted-average sale prices with representative figures including $64.43, $65.47, $66.44, and ranges from $64.00 to $67.29 depending on the lot.